Cargando…
Exploring the Role of Novel Medical Therapies for Aggressive Pituitary Tumors: A Review of the Literature—“Are We There Yet?”
Aggressive pituitary tumors account for up to 10% of pituitary tumors and are characterized by resistance to medical treatment and multiple recurrences despite standard therapies, including surgery, radiotherapy, and chemotherapy. They are associated with increased morbidity and mortality, particula...
Autores principales: | Lamb, Lydia S., Sim, Hao-Wen, McCormack, Ann I. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7072681/ https://www.ncbi.nlm.nih.gov/pubmed/32012988 http://dx.doi.org/10.3390/cancers12020308 |
Ejemplares similares
-
Case Report: A Case of Pituitary Carcinoma Treated With Sequential Dual Immunotherapy and Vascular Endothelial Growth Factor Inhibition Therapy
por: Lamb, Lydia S., et al.
Publicado: (2020) -
Aggressive pituitary tumours and carcinomas, characteristics and management of 171 patients
por: Burman, Pia, et al.
Publicado: (2022) -
Are we there yet?
por: Wise, Jo Ann
Publicado: (2015) -
Pituitary hyperplasia: case series and literature review of an under-recognised and heterogeneous condition
por: De Sousa, Sunita M C, et al.
Publicado: (2015) -
Are we there yet?
por: Swann, Nicole
Publicado: (2019)